Cardinal Health warned Thursday that if President Donald Trump follows through with threatened tariffs next month, higher ...

Cardinal Health's pharmaceutical and specialty solutions segment profit increased 7% to $531 million in the second quarter.

Drug distributor Cardinal Health on Thursday raised its fiscal 2025 adjusted profit forecast as strong demand for costly specialty medicines and branded drugs drove sales at its pharmaceuticals unit.

Cardinal Health reported an increase in revenue for two of its segments, while the departure of Optimum impacted its Pharmaceuticals segment.

In addition, it manufactures, sources, and distributes Cardinal Health branded medical, surgical, and laboratory products and devices that include exam and surgical gloves; needles, syringe ...

Cardinal Health, Inc. CAH reported second-quarter fiscal 2025 adjusted earnings per share (EPS) of $1.93, which beat the ...

Cardinal Health, Inc. CAH is scheduled to report fiscal second-quarter 2025 results on Jan. 30, before the opening bell. In ...

Morgan Stanley analyst Erin Wright maintained a Buy rating on Cardinal Health (CAH – Research Report) today and set a price target of $136.00.

Cardinal Health has reported second quarter revenue for its “other” businesses, which includes at-Home Solutions, increased 13% to $1.3 billion.

In a report released yesterday, Stephen Baxter from Wells Fargo maintained a Hold rating on Cardinal Health (CAH – Research Report), with a ...

Cardinal Health gets downgraded to a hold ... A key risk in this segment is that of regulatory and legal costs involving medical products and drugs. From its profile, what this firm is known ...

sources and distributes Cardinal Health branded medical, surgical, and laboratory products. The company was founded by Robert D. Walter in 1979 and is headquartered in Dublin, OH.